Overview

Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery

Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
The investigators aim to evaluate how different timing of anti-VEGF intravitreous injections affect visual acuity (BCVA) in patients with diabetic macular edema who are undergoing cataract surgery; and to evaluate how different timing of anti-VEGF intravitreous affect OCT CSF thickness and total number of postoperative injections in patients with diabetic macular edema who are undergoing cataract surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Second Military Medical University
Treatments:
Bevacizumab
Endothelial Growth Factors
Ranibizumab